Drugs Made In America Acquisition (DMAA) Competitors $10.31 +0.01 (+0.10%) As of 10/23/2025 01:28 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsOwnershipSEC FilingsShort InterestTrendsBuy This Stock DMAA vs. SAFE, ORC, IPXX, DEA, CSR, SBR, GETY, PLYM, PAX, and FBRTShould you be buying Drugs Made In America Acquisition stock or one of its competitors? The main competitors of Drugs Made In America Acquisition include Safehold (SAFE), Orchid Island Capital (ORC), Inflection Point Acquisition Corp. II (IPXX), Easterly Government Properties (DEA), Centerspace (CSR), Sabine Royalty Trust (SBR), Getty Images (GETY), Plymouth Industrial REIT (PLYM), Patria Investments (PAX), and Franklin BSP Realty Trust (FBRT). These companies are all part of the "trading" industry. Drugs Made In America Acquisition vs. Its Competitors Safehold Orchid Island Capital Inflection Point Acquisition Corp. II Easterly Government Properties Centerspace Sabine Royalty Trust Getty Images Plymouth Industrial REIT Patria Investments Franklin BSP Realty Trust Drugs Made In America Acquisition (NASDAQ:DMAA) and Safehold (NYSE:SAFE) are both small-cap trading companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership. Which has better earnings and valuation, DMAA or SAFE? Safehold has higher revenue and earnings than Drugs Made In America Acquisition. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDrugs Made In America AcquisitionN/AN/AN/AN/AN/ASafehold$365.68M3.05$105.76M$1.4310.86 Does the media favor DMAA or SAFE? In the previous week, Safehold had 5 more articles in the media than Drugs Made In America Acquisition. MarketBeat recorded 5 mentions for Safehold and 0 mentions for Drugs Made In America Acquisition. Safehold's average media sentiment score of 0.62 beat Drugs Made In America Acquisition's score of 0.00 indicating that Safehold is being referred to more favorably in the news media. Company Overall Sentiment Drugs Made In America Acquisition Neutral Safehold Positive Is DMAA or SAFE more profitable? Safehold has a net margin of 27.45% compared to Drugs Made In America Acquisition's net margin of 0.00%. Safehold's return on equity of 4.70% beat Drugs Made In America Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Drugs Made In America AcquisitionN/A N/A N/A Safehold 27.45%4.70%1.61% Do institutionals and insiders have more ownership in DMAA or SAFE? 70.4% of Safehold shares are held by institutional investors. 3.5% of Safehold shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend DMAA or SAFE? Safehold has a consensus target price of $19.89, suggesting a potential upside of 28.03%. Given Safehold's stronger consensus rating and higher probable upside, analysts clearly believe Safehold is more favorable than Drugs Made In America Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Drugs Made In America Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Safehold 0 Sell rating(s) 7 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.30 SummarySafehold beats Drugs Made In America Acquisition on 11 of the 11 factors compared between the two stocks. Get Drugs Made In America Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DMAA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAA vs. The Competition Export to ExcelMetricDrugs Made In America AcquisitionInvestment Offices IndustryFinancial SectorNASDAQ ExchangeMarket Cap$300.47M$281.92M$4.86B$10.57BDividend YieldN/AN/A4.41%4.83%P/E RatioN/AN/A22.5328.46Price / SalesN/AN/A1,453.37188.31Price / CashN/A18,601.67127.7460.64Price / BookN/AN/A2.146.53Net IncomeN/A$12.92M$1.22B$276.75M7 Day Performance0.10%0.01%0.47%0.93%1 Month PerformanceN/A1.78%0.53%1.41%1 Year PerformanceN/A5.88%38.75%31.59% Drugs Made In America Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMAADrugs Made In America AcquisitionN/A$10.31+0.1%N/AN/A$300.47MN/A0.002SAFESafehold4.2986 of 5 stars$15.45-0.8%$19.89+28.7%-33.5%$1.12B$365.68M10.80120Upcoming EarningsORCOrchid Island Capital2.7747 of 5 stars$7.31+0.7%N/A-4.6%$1.06B$241.58M36.552,018News CoverageEarnings ReportShort Interest ↑IPXXInflection Point Acquisition Corp. IIN/A$33.68-10.3%N/A+126.9%$1.05BN/A0.00N/AGap DownHigh Trading VolumeDEAEasterly Government Properties3.758 of 5 stars$22.01-2.4%$26.41+20.0%-35.6%$1.02B$302.05M53.6850Upcoming EarningsDividend AnnouncementCSRCenterspace3.218 of 5 stars$60.71+1.4%$68.00+12.0%-15.7%$1.00B$260.98M-33.73470News CoveragePositive NewsSBRSabine Royalty Trust1.7899 of 5 stars$67.26-1.0%N/A+15.4%$990.38M$83.17M13.352,020News CoverageGETYGetty Images3.0742 of 5 stars$2.18-7.6%$4.03+84.6%-44.7%$978.96M$939.29M-7.791,700PLYMPlymouth Industrial REIT2.4491 of 5 stars$22.03+0.5%$21.33-3.2%+3.8%$977.07M$198.35M7.6540News CoverageAnalyst DowngradePAXPatria Investments2.3292 of 5 stars$14.34-2.0%$14.00-2.4%+31.1%$953.93M$397.39M28.68390FBRTFranklin BSP Realty Trust3.801 of 5 stars$10.63-0.3%$14.67+38.0%-16.7%$877.05M$516.24M10.85N/APositive NewsUpcoming Earnings Related Companies and Tools Related Companies SAFE Alternatives ORC Alternatives IPXX Alternatives DEA Alternatives CSR Alternatives SBR Alternatives GETY Alternatives PLYM Alternatives PAX Alternatives FBRT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DMAA) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredRefund From 1933: Trump’s Reset May Create Instant WealthFed vs. Trump - A War With American Wealth At Stake The Fed's defiance of Trump thickens the plot to contro...American Hartford Gold | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIt’s Time to Buy “the NVIDIA of Quantum Computing”Yahoo Finance wrote that investing in quantum computing could... "Lead to life-changing returns... and make...Brownstone Research | SponsoredApple's secret partnerThe Tiny Company Apple Can’t Live Without A tiny company holds the key to Apple’s biggest breakthrough sinc...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Drugs Made In America Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Drugs Made In America Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
